Livestock genetic engineering and precision breeding

01Overview and value chain

Markers: [EC: FDA Guidance for Industry #187 (Intentionally Altered Genomic DNA in Animals) | OECD: Agricultural biotechnology | Regulator: FDA (USA), CFIA (Canada), MARA (China)]

Livestock genetic engineering combines CRISPR-Cas9 gene editing with genomic selection to accelerate traits that classical breeding reaches only after many generations. Porcine Reproductive and Respiratory Syndrome (PRRS) alone costs US pork producers an estimated $1.2 billion a year, and a single exon deletion in the CD163 receptor gene removes the virus’s entry point without adding any foreign DNA. The US FDA issued its first low-risk determination for an intentionally altered genomic DNA (IGA) in cattle on March 7, 2022, covering two PRLR-edited “SLICK” lines; by 2025–2026 the same low-risk framework had cleared a heat-tolerance edit and a PRRS-resistance edit for commercial use, while Canada’s food-safety regulators completed an independent review in parallel. Research groups outside the big three regulatory blocs are moving in parallel: India’s first gene-edited farm animal, a myostatin-pathway-edited sheep, took a single university team roughly six years and near 400 embryo- transfer trials to confirm.

Key directions of livestock genetic engineering:

1. Disease-resistance editing (Disease-Resistance Gene Editing): single receptor-gene deletions (CD163 for PRRS) that block viral entry rather than boosting immunity, avoiding any transgene insertion.
2. Thermotolerance editing (Thermotolerance Gene Editing): introducing naturally occurring heat-tolerance alleles (PRLR-SLICK) from tropically adapted cattle breeds into high-yield dairy and beef lines via CRISPR-Cas9.
3. Genomic selection and sexed semen (Genomic Selection & Sexed Semen): SNP-chip genotyping of animals as young as ~6 months, paired with sex-sorted semen, that raises genetic gain without altering any genome.
4. Public-sector founder-animal programs (Public-Sector Gene Editing): university and national-institute programs in India and China producing the first confirmed gene-edited founder animals in each country, ahead of any national commercial-approval pathway.

Sectoral value chain

[trait discovery] ──> [edit design] ──> [founder production] ──> [regulatory review]
                                                                        │
                                                                (risk-based
                                                                 determination)
                                                                        │
                                                                        ▼
[commercial herd] <─── [genomic selection] <─────────────────────────┘

Value chain levels

Cross-cutting technologies of the sector:

• CRISPR-Cas9 site-directed nucleases (CRISPR-Cas9 Site-Directed Nucleases): introduce single-base or short-exon edits that replicate existing natural alleles.
• Somatic cell nuclear transfer (Somatic Cell Nuclear Transfer): clones edited donor cells into enucleated oocytes to derive founder animals.
• SNP-chip genomic evaluation (SNP-Chip Genomic Evaluation): genome-wide marker panels that estimate breeding values without any gene editing.

02US

The US holds the lead regulatory pathway: the FDA’s risk-based framework for intentionally altered genomic DNA in animals has cleared both a thermotolerance and a disease-resistance edit for the food supply.

FDA low-risk determinations, IGA guidance, genomic-selection adoption

• FDA Guidance for Industry #187: the risk-based review track that classifies genomic alterations mirroring natural alleles as low-risk rather than requiring a full new-animal-drug approval.
• Acceligen PRLR-SLICK determination (March 7, 2022): the first FDA low-risk clearance for a gene-edited cattle line, covering two heat-tolerant lines and their offspring.
• Genomic selection at scale: US dairy herds routinely genotype heifers at roughly six months of age, combining SNP-chip evaluation with sexed and beef semen to raise genetic merit without any editing.

03CN

China’s activity sits at the research stage: university groups are publishing CRISPR-edited livestock embryo work, while the national biosafety framework has not yet opened a commercial-approval pathway for gene-edited farm animals.

CRISPR dairy-cattle heat tolerance, MARA biosafety review, cloning-scale infrastructure

• Inner Mongolia Agricultural University PRLR/SCNT program: CRISPR-Cas9 editing of a 20–150 bp region of the bovine PRLR gene, combined with somatic cell nuclear transfer, to study heat-stress resilience in dairy cow embryos.
• MARA biosafety review track: gene-edited animal research is evaluated case-by-case; unlike the US and Canada there is no standing commercial-approval pathway yet for gene-edited livestock products.
• Large-scale cloning infrastructure: China’s existing industrial-scale cattle-cloning capacity is an adjacent production base that gene-edited lines could eventually multiply through, once a commercial pathway opens.

04EU

The EU proper still applies its pre-2001 GMO framework to gene-edited farm animals, while the UK has moved fastest among European jurisdictions with a dedicated precision-breeding regime and an FDA-adjacent commercial approval.

UK Precision Breeding Act, EU GMO-directive gap, swine disease-resistance R&D

• Genus plc / PIC PRRS-resistant pig program: a CD163-exon deletion that blocks the PRRS virus’s cell-entry point; approved by the FDA on April 30, 2025, and by Health Canada and the CFIA on January 23, 2026.
• UK Precision Breeding Act (2023): enacted for plants first, with secondary legislation for precision-bred animals still pending as of 2026.
• EU Directive 2001/18 gap: the EU-27 continues to regulate gene-edited farm animals under its original GMO directive, with no dedicated animal precision-breeding pathway yet in force.

05Leading companies and research institutes

06Tech stack and innovations

The stack pairs targeted gene editing with population-scale genomic evaluation.

1. CRISPR-Cas9 intentional genomic alterations (CRISPR-Cas9 IGAs):
   • edits replicate alleles that already occur naturally in some breeds rather than inserting foreign DNA.
   • case: the FDA classified the Acceligen PRLR edit as low-risk specifically because it mirrors the natural short-hair allele found in Criollo-derived cattle.
2. Somatic cell nuclear transfer (Somatic Cell Nuclear Transfer):
   • clones an edited donor cell’s nucleus into an enucleated oocyte to derive founder gene-edited embryos.
   • case: SKUAST-Kashmir needed roughly 400 embryo transfers over six years to confirm a single successfully edited lamb, illustrating SCNT’s low efficiency ceiling.
3. SNP-chip genomic selection (SNP-Chip Genomic Selection):
   • genome-wide marker genotyping estimates breeding values months before an animal’s own performance data exists.
   • case: US dairy heifers are genotyped at roughly six months of age on average, ahead of any breeding decision.

07Value chains and production pipelines

Industrial pipeline of an intentional genomic alteration in livestock (FDA Guidance #187)

┌───────────────────────────┐      ┌───────────────────────────┐
│ 1. Trait/allele discovery │ ───> │ 2. Edit design & delivery │
└───────────────────────────┘      └───────────────────────────┘
                                                 │
                                                 ▼
┌───────────────────────────┐      ┌───────────────────────────┐
│ 4. Regulatory risk review │ <─── │ 3. Founder confirmation   │
└───────────────────────────┘      └───────────────────────────┘
              │
              ▼
┌───────────────────────────┐      ┌───────────────────────────┐
│ 5. Herd multiplication    │ ───> │ 6. Commercial deployment  │
└───────────────────────────┘      └───────────────────────────┘

Stage 1: Trait/allele discovery

Breed surveys identify a naturally occurring resistance or tolerance allele — the PRLR short-hair allele in Criollo cattle, or the CD163 receptor variant that blocks PRRS entry.

Stage 2: Edit design & delivery

A CRISPR-Cas9 construct is designed to reproduce the natural allele, delivered by zygote microinjection or into a donor cell line for cloning.

Stage 3: Founder confirmation

Edited embryos are gestated to term and genotyped; SKUAST-Kashmir’s program needed close to 400 embryo transfers over six years to confirm one correctly edited lamb.

Stage 4: Regulatory risk review

A risk-based agency review compares the edited genome against natural variation; the FDA’s first cattle determination took from initial submission to a March 7, 2022 low-risk clearance.

Stage 5: Herd multiplication

SNP-chip genomic selection and sexed semen expand the edited line into a commercial-scale herd without further editing.

Stage 6: Commercial deployment

Processor and export-market acceptance is confirmed; as of 2026 no major US milk processor had yet committed to a branded price premium for gene-edited-line milk, even after full regulatory clearance.